Epcoritamab: all 50 studies that test it

Page 1 of 1. Open to participants first (36), then studies with results posted, then the rest; newest registration first within each.

• Epcoritamab as Consolidative Therapy for Waldenstr(SqrRoot)(Delta)m Macroglobulinemia (WM) Treated With a Bruton Tyrosine Kinase Inhibitor (BTKi)Not yet recruitingNCT07882173Phase 2
• Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKINot yet recruitingNCT07819214Phase 2
• Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell TherapyNot yet recruitingNCT07814001Phase 2
• Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphomaNot yet recruitingNCT07783594Phase 2
• Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 AlterationsNot yet recruitingNCT07738887Phase 2
• Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit PatientsNot yet recruitingNCT07714421Phase 1
• Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK StudyNot yet recruitingNCT07662928Phase 2
• Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin LymphomaNot yet recruitingNCT07588698Phase 2
• External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCLRecruitingNCT07528352Phase 1
• Low Dose Epcoritamab Plus GemOx in R/R DLBCLRecruitingNCT07451652Phase 2
• Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingNCT07365306Phase 2
• Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity TrialRecruitingNCT07218510Phase 2
• Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)RecruitingNCT07197307Phase 2
• Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell LymphomaRecruitingNCT07126236Phase 2
• Study of Epcoritamab as a Consolidation Therapy in CLL/SLLRecruitingNCT07108998Phase 2
• Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaRecruitingNCT07097363Phase 2
• A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)RecruitingNCT07082868Phase 1
• Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and RituximabRecruitingNCT06931652Phase 2
• Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell LymphomaRecruitingNCT06919939Phase 2
• Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell LymphomaRecruitingNCT06905509Phase 2
• Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)RecruitingNCT06796998Phase 2
• Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell LymphomaRecruitingNCT06723457Phase 2
• Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative DisordersRecruitingNCT06672705Phase 1
• Epco, Zanu, Ritux for R/R FL or MZLRecruitingNCT06563596Phase 2
• Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin LymphomaRecruitingNCT06536049Phase 1/2
• Epcoritamab in Previously Treated WMRecruitingNCT06510491Phase 2
• Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront ChemoimmunotherapyRecruitingNCT06510361Phase 2
• Epcoritamab-CAR T Cells for Large B-cell LymphomasRecruitingNCT06458439Phase 2
• Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to EpcoritamabRecruitingNCT06447376Phase 1
• MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell LymphomaRecruitingNCT06414148Phase 2
• Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCLRecruitingNCT06287398Phase 2
• Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T TherapyRecruitingNCT06238648Phase 2
• Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell LymphomaRecruitingNCT06045247Phase 2
• Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapyRecruitingNCT05848765Phase 2
• Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLLRecruitingNCT05791409Phase 1/2
• Epcoritamab and Rituximab for First-line Follicular LymphomaRecruitingNCT05783609Phase 2
• A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in ChinaActive, not recruitingNCT07226752Phase 3
• A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell LymphomaWithdrawnNCT07030699Phase 2
• Epcoritamab in Chronic Lymphocytic Leukemia and Richter SyndromeActive, not recruitingNCT06676033Phase 1
• Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular LymphomaSuspendedNCT06575686Phase 2
• A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell LymphomaActive, not recruitingNCT06508658Phase 3
• Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular LymphomaActive, not recruitingNCT06191744Phase 3
• Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular LymphomaActive, not recruitingNCT06112847Phase 2
• A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)Active, not recruitingNCT05578976Phase 3
• A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular LymphomaActive, not recruitingNCT05451810Phase 2
• Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular LymphomaActive, not recruitingNCT05409066Phase 3
• Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of EpcoritamabActive, not recruitingNCT05206357Phase 1
• A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)Active, not recruitingNCT04628494Phase 3
• Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)Active, not recruitingNCT04542824Phase 1/2
• First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell LymphomaActive, not recruitingNCT03625037Phase 1/2

← Epcoritamab overview